Want to see YARW full AI Analyst Report?
YARW Stock Chart & Stats
$30.21
$0.09(0.20%)
At close: 4:00 PM EDT
$30.21
$0.09(0.20%)
Day’s Range― - ―
52-Week Range$16.04 - $46.97
Previous CloseN/A
Volume2.93K
Average Volume (3M)134.04K
Market Cap
$188.75M
Enterprise Value$625.88K
Total Cash (Recent Filing)$22.93M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta1.65
Next Earnings
Nov 05, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield100.5%
Share Statistics
EPS (TTM)-23.45
Shares Outstanding9,437,693
10 Day Avg. Volume142,863
30 Day Avg. Volume134,044
Financial Highlights & Ratios
PEG Ratio0.03
Price to Book (P/B)0.89
Price to Sales (P/S)43.53
P/FCF Ratio-0.75
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue1.30
Enterprise Value/Gross Profit1.33
Enterprise Value/Ebitda-0.03
Forecast
1Y Price Target
$57.00Price Target Upside88.68% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-89
Revenue Forecast (FY)$350.00K
Bulls Say, Bears Say
Bulls Say
Low LeverageAn essentially debt-free balance sheet reduces mandatory financing costs and default risk, giving Yarrow greater flexibility to direct capital toward clinical development. Positive equity also provides a financial base, although its decline shows that this strength must be preserved through disciplined spending.
Strengthened Funding PositionThe sizeable equity raise materially improves funding flexibility for a clinical-stage biotechnology program and can support trials, regulatory work, and corporate operations over the medium term. It strengthens the balance sheet, though the benefit comes with greater share dilution.
Clinical Pipeline ProgressA focused thyroid autoimmune pipeline with regulatory Fast Track status, advancing clinical trials, and partner-supported development provides a clearer path toward generating value from Yarrow’s lead program. Progress across stages can improve development efficiency and strategic credibility.
Bears Say
Severe Operating LossesYarrow’s revenue base remains far too small to absorb its operating expense structure, leaving the company heavily loss-making despite very high gross margins. Until clinical programs produce meaningful commercial revenue, profitability depends on continued financing and successful execution.
Persistent Cash BurnSustained negative operating and free cash flow means Yarrow is consuming capital rather than internally funding its business. This limits financial resilience and makes future development dependent on available cash, financing access, or eventual improvement in operating performance.
Dilution RiskThe unusually large pre-funded warrant position relative to current common shares creates substantial potential dilution if exercised. Future issuance could reduce existing shareholders’ ownership and influence, while complicating capital structure management as the clinical platform develops.
Yarrow Bioscience News
YARW FAQ
What was Yarrow Bioscience’s price range in the past 12 months?
Yarrow Bioscience lowest stock price was $16.04 and its highest was $46.97 in the past 12 months.
What is Yarrow Bioscience’s market cap?
Yarrow Bioscience’s market cap is $188.75M.
When is Yarrow Bioscience’s upcoming earnings report date?
Yarrow Bioscience’s upcoming earnings report date is Nov 05, 2026 which is in 6 days.
How were Yarrow Bioscience’s earnings last quarter?
Yarrow Bioscience released its earnings results on Aug 13, 2026. The company reported -$2.14 earnings per share for the quarter.
Is Yarrow Bioscience overvalued?
According to Wall Street analysts Yarrow Bioscience’s price is currently Undervalued.
Does Yarrow Bioscience pay dividends?
Yarrow Bioscience pays a Notavailable dividend of $20.1 which represents an annual dividend yield of 100.5%. See more information on Yarrow Bioscience dividends here
What is Yarrow Bioscience’s EPS estimate?
Yarrow Bioscience’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Yarrow Bioscience have?
Yarrow Bioscience has 9,437,693 shares outstanding.
What happened to Yarrow Bioscience’s price movement after its last earnings report?
Yarrow Bioscience reported an EPS of -$2.14 in its last earnings report. Following the earnings report the stock price went down -0.117%.
Which hedge fund is a major shareholder of Yarrow Bioscience?
Currently, no hedge funds are holding shares in YARW
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Yarrow Bioscience Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$57.00 (88.68% Upside)
$57.00 (88.68% Upside)
Hedge Fund Trend
Decreased
By 24.6K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 8.3%
Last 30 Days ▼ 0.9%
Last 30 Days ▼ 0.9%
Technicals
SMA
Negative
20 days / 200 days
Momentum
104.56%
12-Months-Change
Fundamentals
Return on Equity
-70.23%
Trailing 12-Months
Asset Growth
-47.22%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Yarrow Bioscience
Yarrow Bioscience is a clinical-stage biotechnology company focused on developing transformative therapies for autoimmune thyroid diseases. The Company's lead product candidate, YB-101, is a potential first-in-class anti-thyroid stimulating hormone receptor (TSHR) monoclonal antibody designed to directly and rapidly disrupt the central mechanism of both Graves' disease (GD) and thyroid eye disease (TED).
YARW Stock 12 Month Forecast
Average Price Target
$57.00
▲(88.68% Upside)
Technical Analysis
Ownership Overview
16.35% Insiders
4.49% Mutual Funds
<0.01% Other Institutional Investors
75.34% Public Companies and
Individual Investors